Iceland vs Puerto Rico: Tuberculosis patients living with HIV receiving antiretroviral therapy
Iceland
0 patients
in 2014
Puerto Rico
0 patients
in 2021
Iceland rank
141st
Puerto Rico rank
141st
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Iceland
- Puerto Rico
How they compare
Iceland currently reports 0 patients against 0 patients in Puerto Rico, a difference of 0 patients.
Across all 8 years both countries report, Puerto Rico has been ahead every year.
Iceland ranks 141st and Puerto Rico ranks 141st of 183 countries.
Puerto Rico has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Iceland | Puerto Rico | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.3333 patients | 5.67 patients | 5.33 patients | Puerto Rico |
| 2010s | 0 patients | 4.8 patients | 4.8 patients | Puerto Rico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Iceland or Puerto Rico?
- Iceland, at 0 patients against 0 patients in Puerto Rico as of 2014.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Iceland and Puerto Rico?
- 0 patients, with Iceland ahead.
- How many years of comparable data are there for Iceland and Puerto Rico?
- 8 years are reported by both, from 2006 to 2014.
- How do Iceland and Puerto Rico rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Iceland ranks 141st and Puerto Rico ranks 141st of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.